The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial

Mostafa Najafipour ¹ , Farzad Najafipour ² * , Alireza Ostadrahimi ³, Maryam Ghavami ¹, Zohreh Razaghi ², Helda Tutunchi ², Naimeh Mesri Alamdari ² *

Cited by CrossRef:

1- Mesri Alamdari N, Barghaman M, Roshanravan N, Mobasseri M, Tutunchi H, Baharami A, Aliasgarzadeh A, Sadra V. Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial. BMC Res Notes. 2025;18(1) [Crossref]